From the viewpoint that CSL bought Calimmune, that CSL sure know how to monetize biotech prospects (ie: they overtook CBA briefly last week as ASX largest MC), and that Calimmune's biggest effort is based on Benitec IP that it licensed, maybe the only thing we are getting wrong at moment as BLT holders is timing.
CSL's purchase of Calimmune 3 years apparently based on their belief gene therapy, viral delivered, will be a commercial reality within 10 years (~ 2027).
